GlassScriptPhysician profile
Edward S Haight
NPI 1972509818
$26,105.62
in general payments reported to CMS, 2019-2025
73 companies · $2,886 in 2025
The $2,886 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,975 · 2020: $3,794 · 2021: $4,091 · 2022: $4,501 · 2023: $3,599 · 2024: $3,259 · 2025: $2,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,625 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,624.88 |
| Education | $119.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,713.28 | 2019-2025 | Nuplazid, Daybue |
| Ucb, INC. | $1,607.55 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $1,569.00 | 2021-2025 | |
| Eisai INC. | $1,302.84 | 2019-2025 | |
| Csl Behring | $1,267.72 | 2019-2025 | Hizentra |
| Lilly USA, LLC | $1,200.57 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Amgen INC. | $1,195.71 | 2019-2023 | Aimovig |
| Biogen, INC. | $1,058.16 | 2019-2025 | Leqembi, Vumerity, Skyclarys |
| Novartis Pharmaceuticals Corporation | $1,039.86 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,030.66 | 2019-2024 | Austedo Xr, Austedo |
| Sk Life Science, INC. | $833.75 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $820.93 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $741.32 | 2021-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $728.19 | 2020-2025 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $652.77 | 2019-2025 | Epidiolex |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Haight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.